The Radiodermatitis drugs in development market research report provides comprehensive information on the therapeutics under development for Radiodermatitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Radiodermatitis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Radiodermatitis and features dormant and discontinued products.
GlobalData tracks 20 drugs in development for Radiodermatitis by 18 companies/universities/institutes. The top development phase for Radiodermatitis is preclinical with eight drugs in that stage. The Radiodermatitis pipeline has 18 drugs in development by companies and two by universities/ institutes. Some of the companies in the Radiodermatitis pipeline products market are: BioCurity Pharmaceuticals, VasoDynamics and Rion.
The key targets in the Radiodermatitis pipeline products market include Serine/Threonine Protein Kinase B Raf, Prostaglandin G/H Synthase 2, and Tumor Necrosis Factor.
The key mechanisms of action in the Radiodermatitis pipeline product include Histone Deacetylase Inhibitor with one drug in Preclinical. The Radiodermatitis pipeline products include nine routes of administration with the top ROA being Topical and five key molecule types in the Radiodermatitis pipeline products market including Small Molecule, and Synthetic Peptide.
Radiodermatitis overview
Radiodermatitis is an inflammation of the skin caused by radiation. Several treatment factors can be attributed to the varying response of the patients’ skin to radiation therapy; individual fraction size, type of energy, and the use of bolus doses can impact skin reactions. Host factors also may play a role in the development of radiodermatitis; they include genetic factors, personal factors, existing skin integrity issues, comorbid conditions, nutritional status, age, race and ethnicity, medications, sun exposure, smoking, and mobility.
For a complete picture of Radiodermatitis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
